Verrica Pharmaceuticals Inc.
VRCA
$6.82
$0.121.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.18M | 7.57M | 9.21M | 13.91M | 8.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.18M | 7.57M | 9.21M | 13.91M | 8.91M |
| Cost of Revenue | 19.48M | 22.85M | 30.95M | 30.78M | 32.78M |
| Gross Profit | -12.30M | -15.28M | -21.74M | -16.88M | -23.87M |
| SG&A Expenses | 51.33M | 58.82M | 65.94M | 69.91M | 59.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.55M | 73.40M | 84.32M | 92.23M | 83.64M |
| Operating Income | -55.37M | -65.84M | -75.11M | -78.32M | -74.73M |
| Income Before Tax | -65.99M | -76.58M | -84.99M | -86.93M | -80.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.99 | -76.58 | -84.99 | -86.93 | -80.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.99M | -76.58M | -84.99M | -86.93M | -80.74M |
| EBIT | -55.37M | -65.84M | -75.11M | -78.32M | -74.73M |
| EBITDA | -54.53M | -64.88M | -74.19M | -77.52M | -74.05M |
| EPS Basic | -12.01 | -15.36 | -18.27 | -18.77 | -17.47 |
| Normalized Basic EPS | -7.50 | -9.59 | -11.08 | -11.39 | -10.57 |
| EPS Diluted | -12.01 | -15.36 | -18.27 | -18.77 | -17.47 |
| Normalized Diluted EPS | -7.50 | -9.59 | -11.08 | -11.39 | -10.57 |
| Average Basic Shares Outstanding | 25.55M | 20.71M | 18.61M | 18.54M | 18.48M |
| Average Diluted Shares Outstanding | 25.55M | 20.71M | 18.61M | 18.54M | 18.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |